Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)

被引：0

作者：

Hassel, J. ^{[1
,2
]}

Forschner, A. ^{[3
]}

Bluhm, L. ^{[4
]}

Heinzerling, L. ^{[5
]}

Zimmer, L. ^{[6
]}

Utikal, J. ^{[7
,8
]}

Kaehler, K. ^{[9
]}

Schlaak, M. ^{[10
]}

Loquai, C. ^{[11
]}

Gutzmer, R. ^{[12
]}

Kieker, F. ^{[13
]}

Berking, C. ^{[14
]}

Bender, A. ^{[15
]}

Schneider, L. ^{[16
]}

Enk, A. ^{[1
,2
]}

Garbe, C. ^{[3
]}

Weichenthal, M. ^{[9
]}

Schadendorf, D. ^{[6
]}

Hauschild, A. ^{[9
]}

Mohr, P. ^{[4
]}

机构：

[1] Univ Klinikum Heidelberg, Hautklin, Heidelberg, Germany

[2] Univ Klinikum Heidelberg, NCT, Heidelberg, Germany

[3] Univ Klinikum Tubingen, Hautklin, Tubingen, Germany

[4] Elbe Klinikum Buxtehude, Hautklin, Buxtehude, Germany

[5] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany

[6] Univ Klinikum Essen, Hautklin, Essen, Germany

[7] DKFZ, Heidelberg, Germany

[8] Univ Klinikum Mannheim, Klin Kooperat Einheit Dermatoonkol, Heidelberg, Germany

[9] Univ Klinikum Kiel, Hautklin, Kiel, Germany

[10] Univ Klinikum Koln, Hautklin, Cologne, Germany

[11] Univ Klinikum Mainz, Hautklin, Mainz, Germany

[12] Univ Klinikum Hannover, Hautklin, Hannover, Germany

[13] Charite Univ Klinikum, Hautklin, Berlin, Germany

[14] Univ Munchen LMU, Hautklin, Munich, Germany

[15] Univ Klinikum Marburg, Hautklin, Marburg, Germany

[16] Univ Klinikum Ulm, Hautklin, Ulm, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2016年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

FV19

引用

页码：9 / 9

页数：1

共 50 条

[1] Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).
Hassel, Jessica Cecile
Forschner, Andrea
Blum, Leonie
Heinzerling, Lucie
Zimmer, Lisa
Utikal, Jochen
Kahler, Katharina C.
Schlaak, Max
Loquai, Carmen
Gutzmer, Ralf
Kiecker, Felix
Berking, Carola
Bender, Armin
Schneider, Lars
Enk, Alexander
Garbe, Claus
Weichenthal, Michael
Schadendorf, Dirk
Hauschild, Axel
Mohr, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment
Yang, C-K.
Liu, J-H.
Lin, C-C.
Liu, T-C.
Cheng, P-T.
Lin, C-Y.
Hu, H-T.
Cao, C-R.
Huang, W-T.
Chen, L-P.
Chang, W-C.
ANNALS OF ONCOLOGY, 2016, 27
[3] Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).
Rozeman, Elisa A.
Jansen, Yanina
Foppen, MarnixMarnix Heimen Geukes
Schreuer, Max
Wilgenhof, Sofie
Van Thienen, Johannes V.
Haanen, John B. A. G.
Blank, Christian U.
Neyns, Bart
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Pembrolizumab expanded access program (EAP) in Spain: clinical activity.
Arance, Ana
Piulats, Josep M.
Rodas, Ivan Marquez
Manzano, Jose Luis
Berrocal, Alfonso
Algarra, Salvador Martin
Crespo, Guillermo
Rodriguez, Delvys
Guerrero, Miguel Angel Berciano
Soria, Ainara
Ruiz, Elisabeth Perez
Castano, Almudena Garcia
Montagut, Clara
Puertolas, Teresa
Aguado, Carlos
Royo, Maria Angeles
Blanco, Remei
Munoz-Couselo, Eva
Sanchis, Pilar Mut
Gonzalez-Cao, Maria
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP)
Perdon, Karen Mae
Kim, Dae Won
Balmes, Gener C.
VanAnh Trinh
McIntyre, Susan E.
Diab, Adi
Amaria, Rodabe Navroze
Patel, Sapna Pradyuman
Hwu, Patrick
James, Marihella
Philip, Ann
Vardeleon, Anna
Cain, Suzanne
Hwu, Wen-Jen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program
Jeroen, de Filette
Yanina, Jansen
Max, Schreuer
Hendrik, Everaert
Brigitte, Velkeniers
Bart, Neyns
Bert, Bravenboer
ACTA CLINICA BELGICA, 2016, 71 : 19 - 19
[7] EXPANDED-ACCESS PROGRAM (EAP) OF SUNITINIB IN 458 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Sternberg, C. N.
Porta, C.
Bracarda, S.
Carteni, G.
Lo Re, G.
Ruggeri, E. M.
Conte, P.
Monfardini, S.
Gasparini, G.
Ciuffreda, L.
ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
[8] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
Gonzalez-Cao, M.
Arance, A.
Piulats, J. M.
Marquez-Rodas, I.
Manzano, J. L.
Berrocal, A.
Crespo, G.
Rodriguez, D.
Perez-Ruiz, E.
Berciano, M.
Soria, A.
Castano, A. G.
Espinosa, E.
Montagut, C.
Alonso, L.
Puertolas, T.
Aguado, C.
Royo, M. A.
Blanco, R.
Rodriguez, J. F.
Munoz, E.
Mut, P.
Barron, F.
Martin-Algarra, S.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 761 - 768
[9] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
M. González-Cao
A. Arance
J. M. Piulats
I. Marquez-Rodas
J. L. Manzano
A. Berrocal
G. Crespo
D. Rodriguez
E. Perez-Ruiz
M. Berciano
A. Soria
A. G. Castano
E. Espinosa
C. Montagut
L. Alonso
T. Puertolas
C. Aguado
M. A. Royo
R. Blanco
J. F. Rodríguez
E. Muñoz
P. Mut
F. Barron
S. Martin-Algarra
Clinical and Translational Oncology, 2017, 19 : 761 - 768
[10] Durable remissions with Ipilimumab in pretreated metastatic malignant melanoma (MMM) patients (pts): Results of a South African Expanded Access Program (EAP).
Vorobiof, Daniel A.
Rapoport, Bernardo Leon
Dreosti, Lydia Mary
Nosworthy, Adam L.
McAdam, Georgina Laird
Jordaan, Johann Petrus
Donato, Bonnie M. K.
Qatami, Lara
Duvenhage, Hennie
Stander, Tienie
Bergh, Margreet
De Beer, Janetta
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →